Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system used with implanted left ventricular assist devices (LVADs), announces the successful completion of a 180-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump.
|
PETAH TIKVA, Israel, /PRNewswire/ -- Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system used with implanted left ventricular assist devices (LVADs), announces the successful completion of a 180-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump.
Leviticus’ CET technology compliments a LVAD made by Jarvik Heart Inc. which is equipped with a post auricular pedestal, acting together as a hybrid system for the subject. The ongoing trial is being conducted at a renowned animal facility operated by the Catholic University of Leuven, Belgium. This comes as Leviticus has raised additional funds to proceed with the first in human (FIH) trial. Michael Zilbershlag, Leviticus Cardio’s CEO, says, “The combination of the success of the trial reaching six months and the additional resources we have received, means we have what we need to move on to the first in human stage.” “This milestone is a watershed moment for the CET system. The ongoing longevity of the subject gives hope that soon human beings might be able to reap its benefits.” stated Professor Ivan Netuka, MD, Ph.D. of the Institute for Clinical and Experimental Medicine (IKEM), Prague. Peter Hinchliffe, Jarvik Heart Inc. president and COO, stated: “The synergy between Jarvik Heart and Leviticus technologies continues to show clear benefits. Our companies look forward to providing a complete wireless VAD system which will change patients’ lives.” About Leviticus Cardio Founded in 2008, Leviticus Cardio (Leviticus-cardio.com) is a medical device company dedicated to improving the clinical outcome for patients with an implanted left ventricular assist device (LVAD) for the treatment of impaired cardiac function. The Company has received funding from The Trendlines Group (SGX:42T; OTCQX:TRNLY), a leading Israeli early-stage investor, a consortium of acclaimed cardiovascular physicians, private investors and Israel’s Innovation Authority (previously, the Office of the Chief Scientist of the Ministry of Economy). About Jarvik Heart Jarvik Heart, Inc. is a private company that develops miniaturized heart assist devices for the treatment of severe heart failure. The company, formed in 1988, is located in Manhattan, where it conducts development and manufacturing activities. The Jarvik 2000® Ventricular Assist Device has successfully sustained and improved the condition of patients awaiting transplants as well as those who have chosen the device for lifetime use. Contact: Ruden Media Services, Jeremy@jeremyruden.com, (972)-52-4070775
SOURCE Leviticus Cardio |
View original content to download multimedia:
